2,699
Participants
Start Date
April 6, 2016
Primary Completion Date
December 1, 2020
Study Completion Date
December 1, 2020
VRC01
Administered by IV infusion; total dose will vary based on participant's weight
Placebo for VRC01
Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
ACSA CRS, Iquitos
San Miguel CRS, Lima
Lausanne Vaccine and Immunotherapy Center CRS, Lausanne
Harlem Prevention Center CRS, New York
New York Blood Center CRS, New York
Bronx Prevention Research Center CRS, The Bronx
University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester
CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS, Bellavista
Penn Prevention CRS, Philadelphia
George Washington Univ. CRS, Washington D.C.
Chapel Hill CRS, Chapel Hill
The Hope Clinic of the Emory Vaccine Center CRS, Decatur
Alabama CRS, Birmingham
Case Clinical Research Site, Cleveland
UCLA Vine Street Clinic CRS, Los Angeles
Bridge HIV CRS, San Francisco
The Ponce de Leon Center CRS, Atlanta
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston
Fenway Health (FH) CRS, Boston
New Jersey Medical School Clinical Research Center CRS, Newark
Columbia P&S CRS, New York
Vanderbilt Vaccine (VV) CRS, Nashville
Seattle Vaccine and Prevention CRS, Seattle
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro
Barranco CRS, Lima
Via Libre CRS, Lima
National Institute of Allergy and Infectious Diseases (NIAID)
NIH